CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(CRL)
  Report
Delayed Nyse  -  04:00 2022-07-01 pm EDT
218.83 USD   +2.27%
06/28Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
BU
06/28Charles River Laboratories International, Inc. Announces Opening of U.K. Manufacturing Facility
CI
06/24CHARLES RIVER LABORATORIES INTERNATIONAL, INC.(NYSE : CRL) dropped from Russell 1000 Growth-Defensive Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
225.49(c) 217.5(c) 219.46(c) 213.97(c) 218.83(c) Last
355 390 320 335 381 197 596 926 275 655 Volume
-0.37% -3.54% +0.90% -2.50% +2.27% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4 026 M - -
Net income 2022 450 M - -
Net Debt 2022 2 232 M - -
P/E ratio 2022 25,4x
Yield 2022 -
Sales 2023 4 466 M - -
Net income 2023 579 M - -
Net Debt 2023 1 756 M - -
P/E ratio 2023 19,9x
Yield 2023 -
Capitalization 11 118 M 11 118 M -
EV / Sales 2022 3,32x
EV / Sales 2023 2,88x
Nbr of Employees 19 300
Free-Float 98,8%
More Financials
Company
More about the company
Ratings of Charles River Laboratories International, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
06/28Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
BU
06/28Charles River Laboratories International, Inc. Announces Opening of U.K. Manufacturing ..
CI
06/24CHARLES RIVER LABORATORIES INTERNATI : CRL) dropped from Russell 1000 Growth-Defensive Ind..
CI
06/24CHARLES RIVER LABORATORIES INTERNATI : CRL) dropped from Russell 1000 Value-Defensive Inde..
CI
06/24CHARLES RIVER LABORATORIES INTERNATI : CRL) dropped from Russell 1000 Defensive Index
CI
06/23Charles River Laboratories to Work With Ziphius Vaccines to Manufacture Starting Materi..
MT
06/23Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
BU
06/23Charles River Laboratories International, Inc. and Ziphius Vaccines NV Collaborates to ..
CI
06/13Charles River Laboratories Working With ASC Therapeutics to Manufacture Hemophilia A Dr..
MT
06/13Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene The..
BU
06/13Charles River Laboratories International, Inc. and ASC Therapeutics, Inc. to Scale Manu..
CI
06/09TRANSCRIPT : Charles River Laboratories International, Inc. Presents at William Blair’..
CI
06/08Moderna, Roku rise; Scotts Miracle-Gro, Charles River fall
AQ
06/08TRANSCRIPT : Charles River Laboratories International, Inc. Presents at 2022 Jefferies Glo..
CI
06/08CHARLES RIVER LABORATORIES INTERNATI : Regulation FD Disclosure - Form 8-K
PU
More news
News in other languages on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
06/28Charles River Laboratories International, Inc. annonce l'ouverture d'un site de fabrica..
06/23Les Laboratoires Charles River vont collaborer avec Ziphius Vaccines pour fabriquer des..
06/23Charles River Laboratories International, Inc. et Ziphius Vaccines NV collaborent pour ..
06/13Les Laboratoires Charles River collaborent avec ASC Therapeutics pour la fabrication d'..
06/13Charles River Laboratories International, Inc. et ASC Therapeutics, Inc. vont mettre à ..
More news
Analyst Recommendations on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
More recommendations
Chart CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Duration : Period :
Charles River Laboratories International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 218,83 $
Average target price 326,85 $
Spread / Average Target 49,4%
EPS Revisions
Managers and Directors
James C. Foster General Counsel
Flavia H. Pease Chief Financial Officer & Executive Vice President
Arthur C. Hubbs Chief Information Officer & Senior Vice President
Birgit Girshick Chief Operating Officer & Executive Vice President
Matthew L. Daniel Senior Corporate Counsel
Sector and Competitors
1st jan.Capi. (M$)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.-41.92%11 118
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.60%19 031